Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Merrimack Pharmaceuticals (MACK) News Today

Merrimack Pharmaceuticals logo
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases Dividend to $15.10 Per Share
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced a dividend on Thursday, May 16th. Investors of record on Tuesday, May 21st will be paid a dividend of 15.10 per share by the biopharmaceutical company on Friday, May 17th. This represents a yield of 99.87%. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from Merrimack Pharmaceuticals's previous dividend of $1.50.
MACK Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above 200 Day Moving Average of $13.19
Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Crosses Above Two Hundred Day Moving Average of $13.19
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Sees Large Drop in Short Interest
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Free Report) was the recipient of a large drop in short interest in February. As of February 29th, there was short interest totalling 774,100 shares, a drop of 5.9% from the February 14th total of 822,900 shares. Based on an average daily volume of 92,100 shares, the days-to-cover ratio is presently 8.4 days.
Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.93
Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Crosses Above 200 Day Moving Average of $12.93
MACK Mar 2024 14.000 put
MACK Mar 2024 4.000 put
MACK Feb 2024 16.000 put
Ipsen drug approved by FDA for early pancreatic cancer
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.65
Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.65
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.55
Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.55
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals (NASDAQ:MACK) Upgraded at StockNews.com
StockNews.com raised shares of Merrimack Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday.
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals (NASDAQ:MACK) Downgraded by StockNews.com
StockNews.com downgraded shares of Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday.
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Director Eric Andersen Purchases 857 Shares
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Free Report) Director Eric Andersen acquired 857 shares of the stock in a transaction dated Thursday, December 28th. The shares were bought at an average price of $13.35 per share, with a total value of $11,440.95. Following the completion of the transaction, the director now directly owns 534,008 shares of the company's stock, valued at $7,129,006.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals (NASDAQ:MACK) Upgraded to Hold at StockNews.com
StockNews.com raised shares of Merrimack Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday.
Merrimack Pharmaceuticals Inc MACK
Merrimack Reports Third Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Rating Lowered by StockNews.com
StockNews.com downgraded Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday.
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals (NASDAQ:MACK) Downgraded to "Sell" at StockNews.com
StockNews.com cut Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday.
Merrimack Pharmaceuticals, Inc. stock logo
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is 22Nw LP's 6th Largest Position
22Nw LP lowered its holdings in shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Rating) by 17.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,015,048 shares of the biopharmaceutical company's stock after sel
Merrimack Pharmaceuticals, Inc. stock logo
Short Interest in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases By 6.7%
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Rating) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 904,700 shares, a growth of 6.7% from the March 31st total of 847,700 shares. Based on an average daily volume of 91,700 shares, the days-to-cover ratio is currently 9.9 days. Approximately 6.9% of the company's stock are short sold.
Get Merrimack Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

Election warning coming true… (Ad)

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

MACK Media Mentions By Week

MACK Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MACK
News Sentiment

0.92

0.87

Average
Medical
News Sentiment

MACK News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MACK Articles
This Week

0

0

MACK Articles
Average Week

Get Merrimack Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:MACK) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners